$995 | Single User
$4975 | Site License
$9950 | Global License

Oncology Market Access Europe – Payer and Industry Perspectives
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 03 Jul 2014 | 134 | In Stock
Related Topics: Pfizer

Introduction

Introduction


Oncology Market Access Europe – Payer and Industry Perspectives answers your questions:


  • What are payers looking for when making decisions regarding oncology reimbursement?

  • How are HTAs and other challenges affecting market access and what insight do payers offer?

  • How do payer decisions vary from market to market and what factors influence those decisions?

  • What will be the future role of real world data in payer decision-making?

  • What role do risk-sharing schemes, expanded access programmes and other pricing schemes play?

  • What factors should companies take into account when planning market access strategies?

  • Which innovations, such as PD-1 inhibitors, vaccines, personalised medicine and companion diagnostics show the most promise?

  • Oncology market access faces significant and mounting challenges as payers increase data requirements and financial austerity holds sway over decision-making. As pricing and reimbursement requirements become more stringent, issues of development cost, risk and slow market growth are at the forefront. In order to achieve market access success, companies need to adapt their approach and include health outcomes data to meet payer requirements.


    Critical insight


    Based on interviews and surveys with experts from the UK, Germany, Italy, France and Spain, FirstWord’s Oncology Market Access Europe – Payer and Industry Perspectives lays out the current – and growing – challenges facing companies in getting drugs to the European market. Filled with compelling insight into the most pressing issues ranging from changing payer data requirements and financial austerity to the adoption of formalised HTA, the report offers critical strategies, knowledge and a roadmap to the future.


    A report for the whole industry


    The challenges for oncology market access are expected to increase and grow in the near future, making Oncology Market Access Europe – Payer and Industry Perspectives a must-read report not only for those working in market access, brand strategy, business development and licensing, but in biosimilars, payer relationships and drug innovation.


    Puchase Reasons


    Key benefits, features and insights


    Oncology market access is evolving and requires constant updates to keep abreast of changes. In this report, stakeholders will:


  • Gain insight into both the industry and payer perspectives, with particular reference to the increasing importance of robust clinical health outcomes data

  • Understand the key issues affecting access and how they vary between markets

  • Learn about key strategies for success, such as patient access schemes, price-volume agreements and price capping

  • Identify what effective strategies are used by which companies and why they work

  • Understand why the industry needs to adapt to an evolving and challenging landscape

  • Gain insight into how market access issues are driving decisions around R&D

  • Key Features


  • Insight into the innovative strategies being employed to gain market access

  • Overview of new drug approvals and oncology pipeline prospects such as cancer vaccines, niche indications and personalised medicine

  • Examination of the role of HTAs from both payer and industry perspectives

  • Key findings regarding the importance of early inclusion of market access considerations

  • Key Insights


  • How oncology market access varies from country to country and why

  • Complete overview of current oncology market access trends and challenges

  • The payer perspective on everything from transparency in information to the use of health outcomes data in decision making

  • How payers view the HTA process and its role in the short to medium term

  • Key experts interviewed


  • UK payer: Deputy Head of Medicines Management for a PCT with regional and local funding and budgetary decision making responsibility

  • German payer: Head of a national budgetary committee with national, regional and local funding and budgetary decision making responsibility

  • Italian payer: Pharmacist involved in purchasing of drugs and devices for hospital and with national, regional and local funding and budgetary decision making responsibility

  • Spanish payer: Professor of health economics and advisor to the Ministry of Health on pricing and reimbursement issues, with national, regional and local funding and budgetary decision making responsibility

  • French payer – Hospital pharmacist involved in buying medical products including drugs and medical devices for a group of nine hospitals with regional and local funding and budgetary decision making responsibility

  • Former oncology marketing manager, BMS

  • Oncology marketing manager, GSK

  • Oncology medical manager, GSK

  • Oncology market access, Pfizer
  • Table of Contents
    for Oncology Market Access Europe – Payer and Industry Perspectives [Published by FirstWord Pharma]

    • 1.Executive summary

      1.2.Innovation has changed the course of the disease

      1.3.The cost of treating cancer is expected to continue to rise

      1.4.Innovative strategies for obtaining oncology market access are being employed

      1.5.The challenges are expected to continue to grow – and with it, the importance of

      a robust oncology market access strategy

      2.Research objectives and methodology

      3.Introduction.

      3.1.Oncology market access is different for a variety of reasons

      3.2.Despite the challenges, oncology market access is being achieved in many cases

      4.Oncology market dynamics

      4.1.Although a commercially significant sector, oncology has experienced a slowing

      in growth in recent years

      4.2.A number of new oncology drugs were approved in 2013

      4.3.The current oncology pipeline is wide and varied – and offers some interesting prospects

      4.4.The oncology market is dominated by several leading companies –

      but there are many others with one or two key products

      4.4.1.Roche – the market leader and oncology innovator

      4.4.2.Novartis is re-establishing its oncology presence through acquisition

      4.4.3.Pfizer is growing its portfolio through acquisition and targeted research

      4.4.4.BMS is experiencing ongoing growth in oncology and has a promising pipeline

      4.4.5.There are several smaller players with one or two key oncology drugs

      4.5.Cancer vaccines, niche indications and personalised therapies are expected to

      drive the oncology market in the near future

      5.Market access in oncology

      5.1.Obtaining market access for oncology drugs varies across different markets

      5.2.What are the key challenges for oncology market access?

      5.2.1.The payer perspective

      5.2.2.The industry perspective

      5.2.3.Different cancers present different challenges

      5.2.4.Obtaining access in certain markets can be more difficult

      5.2.5.The challenges are expected to become more difficult in the short to medium term

      5.2.5.1.The industry perspective

      5.2.5.2.The payer perspective

      5.3.Current trends in oncology market access

      5.3.1.Value, rather than cost, is increasingly driving decision making

      5.3.2.The pharmaceutical industry is seeking to define value –

      but payers are not necessarily looking at it the same way

      5.4.HTAs are currently widely used in certain markets but they are not expected to

      be implemented in those markets where they are not undertaken

      5.5.The payer perspective

      5.6.The industry perspective

      5.7.Market access considerations are driving R&D decision making for some companies

      5.8.The industry perspective

      5.9.The payer perspective

      6.Strategies for effective oncology market access

      6.1.There are several strategies that can be employed to ensure market access is attainable

      6.1.2.Risk-sharing schemes have been used with varying success

      6.1.3.The payer perspective

      6.1.4.The industry perspective

      6.1.5.Patient access schemes can be used to help boost market access;

      however, the right scheme must be adopted in order to provide benefit

      6.1.6. Pricing schemes are relatively unusual, although informal discounts will be

      given on an individual basis

      6.1.6.1. Launch sequencing can be used as a pricing tool to affect access

      6.1.7.Including market access as a key element of commercial strategy is key to

      market access success

      6.1.7.1.Early inclusion of market access considerations in the development process

      is vital for success at launch

      6.1.7.2.The industry perspective.

      6.1.7.3.The payer perspective

      6.1.7.4.Payers need robust clinical and economic data to make their decisions

      6.2.Early engagement with payers is critical to ensure awareness of a new

      oncology drug and its potential budgetary impact

      6.2.1.The industry perspective

      6.2.2.The payer perspective

      6.2.3.Payers are looking for open and honest communications on a regular basis

      6.3.Advocacy can be a key aspect of obtaining market access, and this is

      expected to become increasingly the case

      7.Contributors

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    134 |

    Number of Pages

    75

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global Oncology Partnering 2010-2016: Deal trends, players and financials
    The Global Oncology Partnering 2010-2016: Deal trends, players and financials report provides an und...
    01 Oct 2016 by Current Partnering USD $3,495 More Info
    Biosimilars in Oncology: Update Bulletin [Feb 2016]
    Introduction new KOL insights on the latest events that have the potential to shape the oncology bio...
    01 Feb 2016 by FirstWord Pharma USD $995 More Info
    Biosimilars in Oncology: KOL Insight
    IntroductionWill physicians ever adopt Biosimilars in Oncology?Sceptical, survival focussed oncologi...
    01 Jan 2016 by FirstWord Pharma USD $7,900 More Info
    Fresenius Kabi Oncology Limited (FKONCO) - Financial and Strategic SWOT Analysis Review
    SummaryFresenius Kabi Oncology Limited (Fresenius Kabi) a subsidiary of Fresenius SE & Co. KGaA, is ...
    08 Nov 2015 by Global Data USD $300 More Info
    Champions Oncology, Inc. (CSBR) - Financial and Strategic SWOT Analysis Review
    SummaryChampions Oncology, Inc. (Champions), formerly known as Champions Biotechnology, Inc., is a b...
    08 Nov 2015 by Global Data USD $300 More Info
    Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (US)
    IntroductionGain exclusive insights on the perceived value and benefits of personalised medicine and...
    01 May 2015 by FirstWord Pharma USD $5,995 More Info
    Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)
    IntroductionGain exclusive insights on the perceived value and benefits of personalised medicine and...
    01 May 2015 by FirstWord Pharma USD $5,995 More Info
    Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies
    IntroductionAs the cancer drug market continues to face significant challenges in an environment of ...
    02 Dec 2014 by FirstWord Pharma USD $3,900 More Info
    Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies
    IntroductionAs the oncology drug market continues to face significant road bumps in terms of develop...
    14 Aug 2014 by FirstWord Pharma USD $3,900 More Info
    Physician Views: Five key pre-ASCO questions on the immuno-oncology race
    Scope The annual meeting of the American Society of Clinical Oncology (ASCO) will take place between...
    29 May 2014 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Oncology Market Access Europe – Payer and Industry Perspectives [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • 360i Research
    • 99Strategy
    • Allied Market Research
    • Asia Market Information & Development Co.
    • Azoth Analytics
    • BioInformant
    • Bizwit Research and Consulting
    • Black Swan Analysis
    • Canadean
    • CBR Pharma Insights
    • CRI
    • Current Analysis
    • Current Partnering
    • Daedal Research
    • Data bridge
    • Delve Insight
    • DPI Research
    • FirstWord Pharma
    • Future Market Insights
    • GBI Research
    • Global Data
    • Global Markets Direct
    • Global Research and Data Services GRDS
    • GMR Data
    • HeyReport
    • HongChun
    • HTStec
    • ICD Research
    • iGATE Research
    • IMARC
    • Industry ARC
    • Inkwood Research
    • IQ4I
    • Jain PharmaBiotech
    • Kelly Scientific
    • La Merie
    • Lifescience Intellipedia
    • LP Information
    • Market Data Forecast
    • Market Research Future
    • Marketline
    • MarketsandMarkets
    • McDerson
    • MedMarket Diligence
    • Meticulous Research
    • MicroMarketMonitor
    • MIReports
    • Mordor Intelligence LLC
    • MP Advisors
    • Occams Business Research
    • Prof Research
    • Progressive Markets
    • ProGrow Pharma Partners
    • Renub
    • Research Impact
    • RNCOS
    • Rockville Research
    • S&P Consulting
    • StratisticsMRC
    • The Business Research Company
    • Triton Market Research
    • Venture Planning Group (VPG)
    • VPA Research